Xlife Sciences AGXSWX:XLS 53 3-1 Month Momentum % is 7.48% as of Jul. 07, 2026. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.25 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,375 Biotechnology companies, Xlife Sciences AG ranks better than 84.22% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-07), Xlife Sciences AG's 3-1 Month Momentum % is 7.48%.
The industry rank for Xlife Sciences AG's 3-1 Month Momentum % or its related term are showing as below:
XSWX:XLS's 3-1 Month Momentum % is ranked better than 84.22% of 1375
companies
in the Biotechnology industry
Industry Median: -8.46
vs XSWX:XLS: 7.48
Xlife Sciences AG (XSWX:XLS) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Xlife Sciences AG 3-1 Month Momentum % Related Terms
XSWX:XLS vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Xlife Sciences AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's 3-1 Month Momentum % falls into.
Xlife Sciences AG (XSWX:XLS) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a 3-1 Month Momentum % of 7.48% as of Jul. 07, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #217 out of 1375 companies in the Biotechnology industry, placing it in the top 15.8%.
Is Xlife Sciences AG's 3-1 Month Momentum % too high?
Xlife Sciences AG's current 3-1 Month Momentum % is 7.48%. Based on the distribution chart, Xlife Sciences AG ranks #217 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #217 out of 1375 companies for 3-1 Month Momentum %. This places Xlife Sciences AG in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current 3-1 Month Momentum % is 7.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.25, compared to a current price of CHF18.15 — trading 150.3% above its estimated fair value. The current 3-1 Month Momentum % is 7.48%. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current 3-1 Month Momentum % is 7.48% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF18.15 is trading 150.3% above its estimated GF Value™ of CHF7.25.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
3-1 Month Momentum %: 7.48%
GF Value™: CHF7.25 vs. price of CHF18.15 (150.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 